Bristol-Myers Squibb, Pfizer Gain Approval on Treatment for Stroke, Systemic Embolism

The anticoagulant from Bristol-Myers Squibb and Pfizer have attained approval for the drug in adult patients with nonvalvular atrial fibrillation.

Bristol-Myers Squibb and Pfizer announced today that the European Commission has approved ELIQUIS® (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors. ELIQUIS is the only oral anticoagulant that has demonstrated superior risk reduction versus warfarin in the three important outcomes of stroke and systemic embolism, major bleeding, and all-cause mortality. ELIQUIS is an oral direct Factor Xa inhibitor, part of a novel therapeutic class.

No votes yet
Syndicate content